

Abstract: P1080

Title: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

Abstract Type: Poster Presentation

Session Title: Indolent and mantle-cell non-Hodgkin lymphoma - Clinical

Background:

In an early-phase study, the combination of zanubrutinib plus obinutuzumab was well tolerated and associated with an early signal of efficacy in patients with follicular lymphoma (FL) (Tam et al. *Blood Adv* 2020). ROSEWOOD (NCT03332017) is a phase 2, randomized study designed to assess efficacy and safety of zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory (R/R) FL.

Aims:

To present an updated analysis with a median follow-up of 20.2 months.

Methods:

Patients with R/R FL (grade 1-3a) who received ≥ 2 lines of therapy including an anti-CD20 antibody and alkylating agent were randomized 2:1 to receive zanubrutinib plus obinutuzumab or obinutuzumab. Zanubrutinib was given at 160 mg twice daily until progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR) by independent central review. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), time to next treatment (TTNT), overall survival (OS), and safety.

Results:

A total of 217 patients were randomized (145 for zanubrutinib plus obinutuzumab; 72 for obinutuzumab). Median age was 64 years. Of the 217 patients, 114 (52.5%) had a high Follicular Lymphoma International Prognostic Index (FLIPI) score at screening and 123 (56.7%) patients had high tumor burden criteria according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria. Median number of prior lines of therapy was 3 (range, 2-11). A total of 114 (52.5%) patients were refractory to rituximab; 214 (98.6%) patients received prior immunochemotherapy. Prior exposure to anticancer drugs included anthracyclines (80.6%), cyclophosphamide (94.0%), and bendamustine (54.8%). ORR was 69.0% (zanubrutinib plus obinutuzumab) vs 45.8% (obinutuzumab) ($P = 0.0012$). Complete response rate was 39.3% (zanubrutinib plus obinutuzumab) vs 19.4% (obinutuzumab); 18-months DOR rate was 69.3% (zanubrutinib plus obinutuzumab) vs 41.9% (obinutuzumab); median PFS was 28.0 months (zanubrutinib plus obinutuzumab) vs 10.4 months (obinutuzumab) (hazard ratio [HR], 0.50 [95% CI: 0.33, 0.75]; $P = 0.0007$). Median TTNT was not evaluable for zanubrutinib plus obinutuzumab and 12.2 months for obinutuzumab (HR, 0.34 [95% CI: 0.22, 0.52]; $P < 0.0001$). Estimated OS rate at 24 months was 77.3% (zanubrutinib plus obinutuzumab) and 71.4% (obinutuzumab), with median OS not reached (zanubrutinib plus obinutuzumab) and 34.6 months (obinutuzumab). Nonhematologic treatment-emergent adverse events of any grade that occurred more frequently for zanubrutinib plus obinutuzumab vs obinutuzumab ($> 5\%$ difference) were petechiae (6.3% vs 0%) and herpes zoster infection (6.3% vs 0%); in contrast, pyrexia (13.3% vs 19.7%) and infusion-related reaction (2.8% vs 9.9%) occurred more frequently in patients on obinutuzumab. When adjusted for duration of treatment exposure, incidences of infection and cytopenia were similar, and incidence of all grades of hemorrhage was 2.4 (zanubrutinib plus obinutuzumab) vs 1.3 (obinutuzumab) persons per 100 person-months. Two patients in each treatment group reported major hemorrhage. Incidences of atrial fibrillation and hypertension were low and similar in both treatment arms.

Summary/Conclusion:

Zanubrutinib plus obinutuzumab demonstrated meaningful activity and a manageable safety profile in patients

with heavily pretreated R/R FL, representing a potential novel therapy.

Keywords: Non-Hodgkin's lymphoma, Follicular lymphoma, Phase II